The prevalence of comorbid migraine in multiple sclerosis: do multiple sclerosis and migraine really coexist?

Background: Multiple sclerosis (MS) is a chronic inflammatory disease causing multifocal demyelination and axonal damage in the central nervous system. Recent studies indicate that MS patients have a higher prevalence of migraine than the general population. This cross-sectional, single-centre study assessed migraine prevalence in MS patients receiving disease-modifying therapies (DMTs). Methods: A total of 205 MS patients were included. All participants were assessed for migraine diagnosis according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), by a qualified physician. Migraine subtypes (episodic or chronic, with or without aura) were determined per ICHD-3 criteria. Each participant provided data on age, gender, current DMT type and duration, previous DMT history, MS-related symptoms, and MS relapses in the past 12 months. Results: Episodic migraine was identified in 36 patients, corresponding to a prevalence of 17.56% (95% CI (confidence interval): 12.4%–22.8%). Age-stratified analysis revealed higher prevalence in younger participants: 21.4% in those under 40 years (n = 98) compared to 14.0% in those aged 40 years or older (n = 107). The majority of cases (n = 28) presented without aura, with aura occurring in 8 patients. No chronic migraine was detected in the cohort. A total of 193 patients were diagnosed with relapsing-remitting multiple sclerosis (RRMS), 2 with secondary progressive MS (SPMS), and 10 with primary progressive MS (PPMS). No cases of progressive-relapsing MS (PRMS) were reported. Among the participants, 193 were receiving DMT, while 12 patients were not undergoing chronic immunotherapy. No significant correlations were found between migraine occurrence and MS type, type of DMT, disease duration, or Expanded Disability Status Scale (EDSS) score. Conclusions: Migraine does not seem to be less common in MS patients compared to the general population but further, age-stratified and controlled studies are needed to investigate if it is more/as common.

Migraine; Multiple sclerosis; Comorbid migraine

[1] Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. The American Journal of Medicine. 2020; 133: 1380–1390.e2.

[2] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1–211.

[3] Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD. Migraine and tension-type headache are associated with multiple sclerosis: a case-control study. Journal of Clinical Medicine. 2025; 14: 2778.

[4] Abdel Naseer M, Shehata HS, Khalil S, Fouad AM, Abdelghany H. Prevalence of primary headaches in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 2024; 86: 105602.

[5] Mohammadi M, Kankam SB, Salehi S, Mohamadi M, Mohammadi A, Firoozabadi SRD, et al. The association between multiple sclerosis and migraine: a meta-analysis. Multiple Sclerosis and Related Disorders. 2023; 79: 104954.

[6] Mrabet S, Wafa M, Giovannoni G. Multiple sclerosis and migraine: links, management and implications. Multiple Sclerosis and Related Disorders. 2022; 68: 104152.

[7] Wang L, Zhang J, Deng ZR, Zu MD, Wang Y. The epidemiology of primary headaches in patients with multiple sclerosis. Brain and Behavior. 2021; 11: e01830.

[8] Moisset X, Giraud P, Dallel R. Migraine in multiple sclerosis and other chronic inflammatory diseases. Revue Neurologique. 2021; 177: 816–820.

[9] Huang SY, Salomon M, Eikermann-Haerter K. Advanced brain MRI may help understand the link between migraine and multiple sclerosis. The Journal of Headache and Pain. 2023; 24: 113.

[10] Gklinos P, Mitsikostas DD. Migraine in multiple sclerosis patients: potential links and treatment approach. Expert Opinion on Pharmacotherapy. 2023; 24: 1845–1851.

[11] Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. The Lancet. 2021; 397: 1485–1495.

[12] GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology. 2018; 17: 954–976.

[13] GBD 2021 Headache Collaborators; Wijeratne T, Oh J, Kim S, Yim Y, Kim MS, Shin JI, et al. Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050: a Global Burden of Disease study 2021. Cell Reports Medicine. 2025; 6: 102348.

[14] Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. The Journal of Headache and Pain. 2022; 23: 34.

[15] Mirmosayyeb O, Barzegar M, Nehzat N, Shaygannejad V, Sahraian MA, Ghajarzadeh M. The prevalence of migraine in multiple sclerosis (MS): a systematic review and meta-analysis. Journal of Clinical Neuroscience. 2020; 79: 33–38.

[16] Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Carneiro MAD, Chikota EM, et al. Migraine in 746 patients with multiple sclerosis. Archives of Neuropsychiatry. 2019; 77: 617–621.

[17] Gklinos P, Mitsikostas DD. Headache disorders in multiple sclerosis: is there an association? A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders. 2024; 85: 105536.

[18] Gklinos P, Evangelopoulos ME, Velonakis G, Mitsikostas DD. Association between multiple sclerosis lesion location, migraine and tension-type headache: a cross-sectional study. Journal of Clinical Neuroscience. 2025; 136: 111250.

[19] Özer G, Ergün U, İnan LE. Headache in multiple sclerosis from a different perspective: a prospective study. Journal of Clinical and Experimental Investigations. 2018; 9: 9–13.